Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Neoplasm Metastasis 2High Risk Myeloid Malignancies 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Transplantation Conditioning × 90 days × Clear all
NCT07627711 2026-06-04

DUAL-NK-PDAC

Beijing Biotech

Phase 1/2 Recruiting
42 enrolled
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04990323 2026-03-24

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

ExCellThera inc.

Phase 1/2 Completed
13 enrolled

High Risk Myeloid Malignancies

NCT07480928 2026-03-18

DUAL-NK-PDAC

Beijing Biotech

Phase 1/2 Recruiting
42 enrolled
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡